Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.32 |
| ▸ | ALB | P02768 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720716 | 0.92 | FGFR1 (0.44) | FGFR1SLC22A6HPRT1LMNAPDE3A | |
| SCHEMBL13714883 | 0.87 | FGFR1 (0.40) | FGFR1SLC22A6 | |
| SCHEMBL5720714 | 0.83 | FGFR1 (0.39) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL3859402 | 0.77 | FGFR1 (0.41) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL13715041 | 0.77 | FGFR1 (0.41) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6319799 | 0.77 | FGFR1 (0.52) | FGFR1SLC22A6HPRT1LMNATHRB | |
| SCHEMBL6904634 | 0.75 | FGFR1 (0.50) | FGFR1SLC22A6HPRT1LMNATHRB | |
| SCHEMBL3852262 | 0.72 | FGFR1 (0.32) | FGFR1SLC22A6 | |
| SCHEMBL3852267 | 0.72 | FGFR1 (0.32) | FGFR1SLC22A6 | |
| SCHEMBL5280050 | 0.72 | FGFR1 (0.57) | FGFR1SLC22A6HPRT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | FGFR1 3686/4885SLC22A6 1014/4885HPRT1 16/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | FGFR1 3686/4885SLC22A6 1014/4885HPRT1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.